- Home
- Solutions
- By Diseases
- Autoimmune Ophthalmic Diseases
- Dacryoadenitis
In order to further develop preclinical research and targeted therapeutics, understanding the pathogenesis, diagnostic approaches, and therapeutic methodologies of dacryoadenitis is essential. As a research services provider, Protheragen offers specialized and customizable dacryoadenitis diagnostics and therapeutic development solutions.
Dacryoadenitis refers to the inflammatory condition of the lacrimal gland that presents with swelling, pain, and dysfunction of tear production. This condition can be either infectious or non-infectious; the latter is usually more complicated and difficult to manage diagnostically and therapeutically. Often, non-infectious forms of non-infectious dacryoadenitis are autoimmune or idiopathic in nature and thus treatable only with complex strategies.
Fig.1 Therapeutics of non-specific and specific dacryoadenitis. (Singh S., et al., 2022)
Histopathological Analysis
Biopsies uncover unique patterns of inflammation and damage which help in formulating the differential diagnosis of various types of the disease. For instance, lymphoplasmacytic infiltration with accompanying fibrosis is seen in idiopathic dacryoadenitis, whereas IgG4-related disease reveals increased plasma cells positive for IgG4 along with a particular ratio of IgG4 to IgG. Non-caseating granulomas are noted in sarcoidosis-related dacryoadenitis, and cases associated with GPA demonstrate granulo-matous inflammation with accompanying vasculitis.
Serological and Molecular Testing
Systemic involvement and further suspected diagnosis can be corroborated by serological tests like ANA, ANCA, and ACE levels. Elevations in serum IgG4 are suggestive of IgG4 related disease, while positivity for ANCA is indicative of Granulomatosis with Polyangiitis (GPA). Confirmation of certain infectious causes of the disease order physiologic tests can be done using molecular tests like PCR for the identification of specific etiology or autoimmune features. The use of these tests may facilitate the development of diagnostics and therapeutics for dacryoadenitis.
Corticosteroids and Immunosuppressive Agents
Corticosteroids are still the most commonly used medication for all types of dacryoadenitis since they reduce them and get remission. In cases where corticosteroids do not provide relief, immunosuppressive drugs like Methotrexate, Azathioprine, and Mycophenolate Mofetil are used. These drugs modify some parts of the immune system and decrease the level of inflammation and improve the condition in chronic or more severe cases.
Biologic Agents
Rituximab, an anti-CD20 monoclonal antibody, has been successful in treating the more complicated cases of IgG4-related disease and GPA. Rituximab mitigates inflammation and autoimmunity through the depletion of B cells which produces autoantibodies. Other biologics including TNF-alpha inhibitors are also being investigated for their potential usefulness in the therapeutic of severe or unresponsive cases of dacryoadenitis.
Protheragen gives a complete service for creating diagnostics and therapeutics concerning dacryoadenitis. We focus on preclinical research and utilize advanced models and assays to test the safety and efficacy of new therapeutics. Our services are provided for each project individually to offer the optimal therapeutic solutions for dacryoadenitis therapeutics.
Understanding the unique challenges posed by dacryoadenitis, Protheragen provides customized services to address specific research and development needs. If you are interested in our services, please feel free to contact us.
References
Copyright © Protheragen. All rights reserved.